Compare Recursion Pharmaceuticals Inc (RXRX) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Wells Fargo & Co — how do they compare? Recursion Pharmaceuticals Inc trades at $4 (market cap $2.14B), while Wells Fargo & Co trades at $81.96 (market cap $242.71B). The key difference: Wells Fargo & Co is far larger — about 113.4× Recursion Pharmaceuticals Inc's market cap, and Wells Fargo & Co pays a 2.49% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Wells Fargo & Co for 87 Days on average.
| RXRX | WFC | |
|---|---|---|
Market Cap | $2.14B | $242.71B |
Volume | 30,789,535 | 13,542,533 |
Sector | Health | Financials |
52-Week High | $6.79 | $96.40 |
52-Week Low | $2.84 | $73.42 |
Typical Hold Time | 22 Days | 87 Days |
Enterprise Value | $1.66B | $498.47B |
Dividend Yield | — | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Wells Fargo (WFC) trades at $80.26, down 1.53% with a bearish technical signal. The stock shows strong fundamentals with revenue growth to $83.7B in 2025 and improving net margins to 25.49%. Recent positive developments include a credit rating upgrade to 'A-' by S&P and upcoming Q3 earnings. Valuation metrics appear attractive with P/E of 11.67 and P/B of 1.47, trading below the consensus price target of $99.13.
WFC presents a compelling value opportunity with solid profitability and analyst support (46.7% buy ratings), though near-term headwinds include recent earnings misses and bearish technical indicators. The bank's improving credit profile and stable outlook support long-term growth potential, but investors should monitor interest rate sensitivity and execution on earnings expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
